Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 4
Submit an article Journal homepage
107
Views
5
CrossRef citations to date
0
Altmetric
Reviews

Emerging apoptosis agonists for bladder cancer

Chris Protzel University of Rostock, Department of Urology, E. Heydemann Street 6, 18057 Rostock, Germany +49 381 4947801; +49 381 494 7802; [email protected]
&
Oliver W Hakenberg University of Rostock, Department of Urology, E. Heydemann Street 6, 18057 Rostock, Germany +49 381 4947801; +49 381 494 7802; [email protected]
Pages 607-618 | Published online: 22 Sep 2009

Bibliography

  • Botteman MF, Pashos CL, Redaelli A, . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30
  • Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009;27:289-93
  • Ferlay J, Randi G, Bosetti C, . Declining mortality from bladder cancer in Europe. BJU Int 2008;101:11-19
  • Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
  • Ries Lag MD, Krapcho M, Stinchcomb DG, et al. SEER cancer statistics review, 1975-2005. National Cancer Institute, Bethesda. Based on November 2007 SEER data submission, posted to the SEER website. 2008
  • Babjuk M, Oosterlinck W, Sylvester R, . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008;54:303-14
  • Sylvester RJ, van der Meijden AP, Oosterlinck W, . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77
  • Kirkali Z, Chan T, Manoharan M, . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34
  • Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205-19
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
  • Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12
  • Hayakawa K, Takemura G, Koda M, . Sensitivity to apoptosis signal, clearance rate, and ultrastructure of fas ligand-induced apoptosis in in vivo adult cardiac cells. Circulation 2002;105:3039-45
  • Singh AB, Kaushal V, Megyesi JK, . Cloning and expression of rat caspase-6 and its localization in renal ischemia/reperfusion injury. Kidney Int 2002;62:106-15
  • Rohn TT, Head E, Nesse WH, . Activation of caspase-8 in the Alzheimer's disease brain. Neurobiol Dis 2001;8:1006-16
  • Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005;26:263-70
  • Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64
  • Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85
  • McKnight JJ, Gray SB, O'Kane HF, . Apoptosis and chemotherapy for bladder cancer. J Urol 2005;173:683-90
  • Lebedeva I, Raffo A, Rando R, . Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides. J Urol 2001;166:461-9
  • Fuessel S, Herrmann J, Ning S, . Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 2006;232:243-54
  • Duggan BJ, Maxwell P, Kelly JD, . The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J Urol 2001;166:1098-105
  • Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2005;37:719-27
  • Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115:2665-72
  • Boatright KM, Renatus M, Scott FL, . A unified model for apical caspase activation. Mol Cell 2003;11:529-41
  • Nagata S. Apoptotic DNA fragmentation. Exp Cell Res 2000;256:12-18
  • Coultas L, Strasser A. The role of the Bcl-2 protein family in cancer. Semin Cancer Biol 2003;13:115-23
  • Letai A. Pharmacological manipulation of Bcl-2 family members to control cell death. J Clin Invest 2005;115:2648-55
  • Chinnaiyan AM. The apoptosome: heart and soul of the cell death machine. Neoplasia 1999;1:5-15
  • Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9
  • van Loo G, Saelens X, van Gurp M, . The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 2002;9:1031-42
  • Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003;10:26-35
  • Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-7
  • Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181-90
  • Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30
  • Pitti RM, Marsters SA, Lawrence DA, . Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998;396:699-703
  • Clancy L, Mruk K, Archer K, . Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005;102:18099-104
  • Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001;1:50-8
  • Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98
  • Finnberg N, Klein-Szanto AJ, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008;118:111-23
  • Schmaltz C, Alpdogan O, Kappel BJ, . T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med 2002;8:1433-7
  • Inukai T, Zhang X, Goto M, . Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006;20:2119-29
  • Shin MS, Kim HS, Lee SH, . Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001;61:4942-6
  • Fisher MJ, Virmani AK, Wu L, . Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res 2001;7:1688-97
  • Bin L, Thorburn J, Thomas LR, . Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem 2007;282:28189-94
  • Wolf S, Mertens D, Pscherer A, . Ala228 variant of trail receptor 1 affecting the ligand binding site is associated with chronic lymphocytic leukemia, mantle cell lymphoma, prostate cancer, head and neck squamous cell carcinoma and bladder cancer. Int J Cancer 2006;118:1831-5
  • Frank B, Shanmugam KS, Beckmann L, . Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:2002-5
  • Samuels Y, Diaz LAJr, Schmidt-Kittler O, . Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73
  • Martinez-Ferrandis JI, Rodriguez-Lopez R, Milne RL, . Polymorphisms in TRAIL receptor genes and risk of breast cancer in Spanish women. Cancer Biomark 2007;3:89-93
  • Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol 2008;18:1-8
  • Karam JA, Lotan Y, Karakiewicz PI, . Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36
  • Gazzaniga P, Gradilone A, Vercillo R, . Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int J Cancer 1996;69:100-4
  • Adams J, Cuthbert-Heavens D, Bass S, Knowles MA. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett 2005;220:137-44
  • Lee SH, Shin MS, Park WS, . Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 1999;59:3068-72
  • Yamana K, Bilim V, Hara N, . Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005;93:544-51
  • Korkolopoulou P, Goudopoulou A, Voutsinas G, . c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Urology 2004;63:1198-204
  • Grunhagen DJ, de Wilt JH, Graveland WJ, . The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006;106:156-62
  • Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol 2004;5:182-9
  • Ichikawa K, Liu W, Zhao L, . Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001;7:954-60
  • Tolcher AW, Mita M, Meropol NJ, . Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5
  • Pukac L, Kanakaraj P, Humphreys R, . HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41
  • Jin H, Yang R, Ross J, . Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008;14:7733-40
  • Tan ML, Ooi JP, Ismail N, . Programmed cell death pathways and current antitumor targets. Pharm Res 2009;26:1547-60
  • Schimmer AD, O'Brien S, Kantarjian H, . A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:8295-301
  • Bedikian AY, Millward M, Pehamberger H, . Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
  • O'Brien S, Moore JO, Boyd TE, . Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007;25:1114-20
  • Wetzler M, Donohue KA, Odenike OM, . Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia–Cancer and leukemia group B study 10107. Leuk Lymphoma 2008;49:1274-8
  • Fandy TE, Shankar S, Srivastava RK. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60
  • Frew AJ, Lindemann RK, Martin BP, . Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008;105:11317-22
  • Ludwig AT, Moore JM, Luo Y, . Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004;64:3386-90
  • Szanto A, Bognar Z, Szigeti A, . Critical role of bad phosphorylation by Akt in cytostatic resistance of human bladder cancer cells. Anticancer Res 2009;29:159-64
  • Mizutani Y, Wu XX, Yoshida O, . Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil. Oncol Rep 1999;6:979-82
  • Sudarshan S, Holman DH, Hyer ML, . In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther 2005;12:12-18
  • Sun B, Moibi JA, Mak A, . Response of bladder carcinoma cells to TRAIL and antisense oligonucleotide, Bcl-2 or clusterin treatments. J Urol 2009;181:1361-71
  • Mizutani Y, Yoshida O, Miki T, Bonavida B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin Cancer Res 1999;5:2605-12
  • Mizutani Y, Nakao M, Ogawa O, . Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. J Urol 2001;165:263-70
  • Simons MP, O'Donnell MA, Griffith TS. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008;26:341-5
  • Baierlein SA, Distel L, Sieber R, . Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72
  • Shimada O, Wu X, Jin X, . Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology 2007;69:395-401
  • Wu XX, Kakehi Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 2009;15:2039-47
  • Fuessel S, Kueppers B, Ning S, . Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol 2004;171:2471-6
  • Ning S, Fuessel S, Kotzsch M, . siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 2004;25:1065-71
  • Kraemer K, Fuessel S, Kotzsch M, . Chemosensitization of bladder cancer cell lines by human telomerase reverse transcriptase antisense treatment. J Urol 2004;172:2023-8
  • Kunze D, Wuttig D, Kausch I, . Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008;32:1049-56
  • Bilim V, Kasahara T, Hara N, . Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int J Cancer 2003;103:29-37
  • Wang J, Zeng F, Wang L, . Synthetic Smac peptide enhances chemo-sensitivity of bladder cancer cells. J Huazhong Univ Sci Technolog Med Sci 2008;28:304-7
  • Wirger A, Perabo FG, Burgemeister S, . Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 2005;25:4341-7
  • Benimetskaya L, Miller P, Benimetsky S, . Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mol Pharmacol 2001;60:1296-307
  • Bilim V, Kasahara T, Noboru H, . Caspase involved synergistic cytotoxicity of bcl-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Cancer Lett 2000;155:191-8
  • Macoska JA, Adsule S, Tantivejkul K, . -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res 2008;58:323-31
  • Shrader M, Pino MS, Lashinger L, . Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res 2007;67:1430-5
  • Oka N, Tanimoto S, Taue R, . Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 2006;97:1093-8
  • Papageorgiou A, Kamat A, Benedict WF, . Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 2006;5:3032-41
  • Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 2007;6:1022-30
  • Qu W, Kang YD, Zhou MS, . Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells. Urol Oncol 2009 [Epub ahead of print]
  • Kelly WK, Richon VM, O'Connor O, . Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003;9:3578-88
  • Wu AJ, ParkII, Zhaung L, Lee C. Response to a lethal dose of heat shock by a transient up-regulation of clusterin expression followed by down-regulation and apoptosis in prostate and bladder cancer cells. Prostate 2002;53:277-85
  • Zhang H, Kim JK, Edwards CA, . Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15
  • Miyake H, Eto H, Hara I, . Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. J Urol 2004;171:2477-81
  • Miyake H, Hara I, Kamidono S, Gleave ME. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin Cancer Res 2001;7:4245-52
  • Miyake H, Yamanaka K, Muramaki M, . Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Neoplasia 2005;7:171-9
  • Muramaki M, So A, Hayashi N, . Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int 2009;103:384-90
  • Wagner KW, Punnoose EA, Januario T, . Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7
  • Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000;97:10014-19

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.